# To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19

> **NCT04709328** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Sinocelltech Ltd.** · enrollment: 690 (estimated)

## Conditions studied

- COVID-19
- SARS-CoV-2

## Interventions

- **DRUG:** SCTA01
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04709328
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2021-03-28
- **Primary completion:** 2022-01-01
- **Final completion:** 2022-03-01
- **Target enrollment:** 690 (ESTIMATED)
- **Last updated:** 2021-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04709328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04709328, "To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04709328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*